ZNF8 inhibitors are a class of chemical agents specifically designed to modulate the activity of the ZNF8 protein, which is part of the broader family of zinc finger proteins. Zinc finger proteins are characterized by their finger-like protrusions that bind zinc ions, playing a pivotal role in DNA binding, RNA transcription, and protein-protein interactions. The ZNF8 protein, in particular, contains these zinc finger motifs that allow it to interact with DNA and possibly other proteins. The inhibitors targeting ZNF8 are specialized molecules that can interact with the ZNF8 protein to alter its biological activity. The design and discovery of ZNF8 inhibitors involve an intricate understanding of the protein's structure, the specific zinc finger domains it contains, and the precise manner in which it interacts with other molecular entities in the cell.
Creating inhibitors for ZNF8 entails identifying the active or binding sites on the protein that are critical for its function. Researchers employ a variety of techniques, such as computational biology, to predict how small molecules might interact with the ZNF8 protein. Advanced analytical methods, including X-ray crystallography or NMR spectroscopy, are often used to determine the three-dimensional structure of ZNF8, identifying potential grooves or pockets where an inhibitor could bind. The binding of an inhibitor to ZNF8 can inhibit its function by preventing the protein from interacting with DNA or other proteins required for its normal activity. The specificity of these inhibitors is crucial to ensure that they do not interfere with other zinc finger proteins that have distinct and essential roles in cellular processes. Developing inhibitors with high specificity requires detailed knowledge of the differences in the structure and binding preferences between ZNF8 and other zinc finger proteins. The intricate process of designing ZNF8 inhibitors is a testament to the sophisticated nature of molecular interaction and the precision required to affect specific protein functions without unintended consequences.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine is a DNA methyltransferase inhibitor which may demethylate DNA and reactivate silenced genes, potentially altering the expression of various proteins including transcription factors. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA is a histone deacetylase inhibitor which may cause hyperacetylation of histone proteins, leading to a more open chromatin structure and potentially altered gene expression. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide interferes with DNA replication by inhibiting topoisomerase II, which could result in DNA damage and potentially affect transcription factor availability and gene expression. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and can arrest cell division, which might indirectly reduce the expression of certain proteins by halting cell cycle progression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 inhibits the BET family of bromodomain proteins, potentially altering the expression of genes regulated by these epigenetic readers. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which can disrupt protein folding and stability, potentially reducing protein levels. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, potentially affecting the levels of regulatory proteins that control gene expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that may affect various signaling pathways, potentially altering the transcriptional regulation of numerous genes. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 antagonizes MDM2, potentially stabilizing p53 and affecting the expression of p53-regulated genes. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid is a metabolite of vitamin A, which can regulate gene expression by activating nuclear hormone receptors. | ||||||